SCHOTT Pharma AG & Co. KGaA

1SXPGermany

8 filed reports · 129 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

€986M

FY2025 · to Sep 30, 2025

Annual report

Net income

€147M

FY2025 · to Sep 30, 2025

Annual report

Operating income

€201M

FY2025 · to Sep 30, 2025

Annual report

Latest quarter or half year

Revenue

€488M

H1 FY2026 · to Mar 31, 2026

up +1.2% vs €482M

Half-year report

Net income

€39M

Q3 FY2026 · to Jun 30, 2026

down −14.8% vs €45.7M

Q3 report

Operating income

€53.3M

Q3 FY2026 · to Jun 30, 2026

down −15.8% vs €63.2M

Q3 report

Filed reports

8 reports · Sep 2024 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
AnnualBundesanzeiger2132Sep 2024 to Sep 2025
Half YearBundesanzeiger2250Mar 2025 to Mar 2026
Q1Bundesanzeiger271Dec 2024 to Dec 2025
Q3Bundesanzeiger2241Jun 2025 to Jun 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q3q32026-06-302026-06-30134Open
FY2026 Q2half year2026-03-312026-03-31131Open
FY2026 Q1q12025-12-312025-12-3131Open
FY2025annual2025-09-302025-09-3093Open
FY2025 Q3q32025-06-302025-06-30107Open
FY2025 Q2half year2025-03-312025-03-31119Open
FY2025 Q1q12024-12-312024-12-3140Open
FY2024annual2024-09-302024-09-3039Open

Financial data

129 concepts · 694 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

IFRS123 concepts · 680 facts · Sep 2024 to Jun 2026

  • Contract liabilities¹11 · Sep 2024 to Jun 2026
  • Other provisions11 · Sep 2024 to Jun 2026
  • Revenue11 · Mar 2025 to Jun 2026
  • Cost of Revenue10 · Mar 2025 to Jun 2026
  • Income Tax Expense (Benefit)10 · Mar 2025 to Jun 2026
  • Other non-financial assets10 · Sep 2024 to Jun 2026
  • EPS (Basic)9 · Mar 2025 to Jun 2026
  • EPS (Diluted)9 · Mar 2025 to Jun 2026
  • Financial result9 · Mar 2025 to Jun 2026
  • General administrative expenses9 · Mar 2025 to Jun 2026
  • Gross Profit9 · Mar 2025 to Jun 2026
  • Interest Expense9 · Mar 2025 to Jun 2026
  • Interest income9 · Mar 2025 to Jun 2026
  • Net Income9 · Mar 2025 to Jun 2026
  • Net other financial result9 · Mar 2025 to Jun 2026
  • Operating income (EBIT)9 · Mar 2025 to Jun 2026
  • Other operating income9 · Mar 2025 to Jun 2026
  • Profit before income taxes9 · Mar 2025 to Jun 2026
  • Research and development costs9 · Mar 2025 to Jun 2026
  • Selling and Marketing Expense9 · Mar 2025 to Jun 2026
  • Share of profit from investments accounted for using the equity method9 · Mar 2025 to Jun 2026
  • thereof attributable to limited liability shareholders of SCHOTT Pharma AG & Co. KGaA9 · Mar 2025 to Jun 2026
  • thereof attributable to non-controlling interests9 · Mar 2025 to Jun 2026
  • Accounts Payable8 · Sep 2024 to Jun 2026

Segment2 concepts · 10 facts · Mar 2026 to Jun 2026

  • Revenue8 · Mar 2026 to Jun 2026
  • Drug Containment Solutions (DCS)2 · Jun 2026

KPI3 concepts · 3 facts · Mar 2026 to Jun 2026

  • Gross profit margin1 · Jun 2026
  • HVS revenue share1 · Jun 2026
  • Tax rate1 · Mar 2026

APM1 concept · 1 fact · Jun 2026

  • Total1 · Jun 2026

Segments

10 facts

Figures broken down by business line, region, product or another axis the company reports on.

Business segment2 members · 4 facts

  • Drug Containment Solutions (DCS)2 · Jun 2026
  • Drug Delivery Systems (DDS)2 · Jun 2026

Geography4 members · 4 facts

  • Asia and South Pacific1 · Jun 2026
  • EMEA1 · Jun 2026
  • North America1 · Jun 2026
  • South America1 · Jun 2026

Solution type2 members · 2 facts

  • Core1 · Mar 2026
  • High-value solutions (HVS)1 · Mar 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of SCHOTT Pharma AG & Co. KGaA (1SXP) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

SCHOTT Pharma AG & Co. KGaA (1SXP): FY2025 revenue €986M · FactIQ